Abstract
We report a case of a 47-year-old woman with rheumatoid arthritis who developed ocular myasthenia gravis during penicillamine treatment. Her serum contained elevated titers of acetylcholine receptor antibodies, and her symptoms resolved 8 weeks after discontinuation of penicillamine. We review the clinical and laboratory features of this syndrome of penicillamine-induced myasthenia gravis and discuss its pathophysiology and treatment.
MeSH terms
-
Arthritis, Rheumatoid / complications*
-
Arthritis, Rheumatoid / drug therapy
-
Arthritis, Rheumatoid / physiopathology
-
Diplopia / chemically induced
-
Diplopia / complications
-
Diplopia / physiopathology
-
Female
-
Humans
-
Middle Aged
-
Myasthenia Gravis / chemically induced*
-
Myasthenia Gravis / complications
-
Myasthenia Gravis / physiopathology
-
Ocular Motility Disorders / chemically induced*
-
Ocular Motility Disorders / complications
-
Ocular Motility Disorders / physiopathology
-
Oculomotor Muscles / drug effects
-
Penicillamine / adverse effects*
-
Receptors, Cholinergic / blood
Substances
-
Receptors, Cholinergic
-
Penicillamine